EarlySign’s COVID Complications AlgoMarker Identifies individuals at increased risk for having COVID-19 complications. With the goal of prioritizing patients for COVID-19 testing and treatment, this new AlgoMarker aids in triaging patients by reducing chart review time to determine whether they are potentially at high risk for hospitalization, complications, and mortality.

Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s of millions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities

ActX is a genomic decision support service that is tightly integrated within the EHR. With ActX implemented, every time a prescription order is written in the routine medication order workflow, it will be checked for drug-genome interactions and the prescriber alerted as needed. Provider friendly, and CAP accredited initial results will be generated and returned to the provider in the clinical inbasket. A dynamic and up-to-date Genomic Profile for each patient will be available in their chart. Patient genetic data can be imported from any clinically valid source. The knowledgebase content is easily customizable and includes content for pharmacogenomics, actionable genetic risks, and carrier statuses.